{
    "nctId": "NCT05550415",
    "briefTitle": "The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer",
    "officialTitle": "Vimentin Expression-based Therapeutic Response in Triple Negative Breast Cancer Receiving Combination of Simvastatin and NAC: a Randomized, Double-Blind, Placebo-Controlled Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer, Chemotherapy Effect, Simvastatin Adverse Reaction",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 26,
    "primaryOutcomeMeasure": "Vimentin Expression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients with advanced breast cancer (locally advanced and distantly advanced) with triple-negative molecular type confirmed by biopsy and immunohistochemical examination.\n2. The patient planned to receive 8 cycles of AC-T chemotherapy.\n3. Patient age \\> 18 years.\n4. Willing to participate in research by signing informed consent.\n\nExclusion Criteria:\n\n1. The patient is pregnant or breastfeeding.\n2. Patients who have received chemotherapy or are on simvastatin therapy.\n3. Allergy to statins.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}